Intermittent asthma, or mild intermittent asthma, stands as the most prevalent form of asthma. Recent data from the Centers for Disease Control (CDC) reveals that over 20 million adults in the United States have been diagnosed with asthma. Among them, 8 million have encountered one or more asthma attacks within the past year, with 9% of those necessitating emergency department care.

This article aims to explore the latest guidelines on mild intermittent asthma as outlined by various esteemed medical societies in the US. Since the release of “2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group”, there has been an inhaler FDA approved for mild intermittent asthma treatment. The primary focus of this article will be on these guidelines and the recent FDA update.

Part 1 – Current Asthma Guidelines

To start, here is a listing of the current asthma guidelines in the US:

Part 2 – FDA Approvals Since the Most Recent Guidelines

The medications/therapies that have been approved by the FDA since the last asthma clinical guideline published in December 2020:

  • AIRSUPRA® (albuterol and budesonide)
    • AstraZeneca
    • FDA approved on January 10, 2023
    • AIRSUPRA is a combination of albuterol, a beta2-adrenergic agonist and budesonide, a corticosteroid, indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma 18 years of age and older.

Thank you for taking the time to review the current asthma guideline, as well as the recent major changes and FDA approvals that have occurred since publication. We value your feedback and would like to hear your suggestions for future topics to be covered in our guideline series. Please feel free to contact us with any ideas or questions you may have. We look forward to hearing from you.

Copyright © 2024 Guideline Central, All rights reserved.